Transcript Meeting Agenda - มหาวิทยาลัยเทคโนโลยีพระจอมเกล้าธนบุรี

Transformation from operative capability to innovative capability
in Bio-based Agro & Food industries
คณะทร ัพยากรชีวภาพและเทคโนโลยี
มหาวิทยาลัยเทคโนโลยีพระจอมเกล้าธนบุร ี
December 19-2014
1
Pharmaceutical and Vaccine Markets
Source: BioExecutive, 2007 modified
Development Time and Costs
Source: Intercell, 2008
Key Success Factors
Projects
Research and Development
• Access to or discovery of cutting edge technologies
• Project management and technological risk assessment
People
Human Resources Development
•In-house capacity building, “5 years threshold”
•Nationwide capacity building, vaccine networking, controlling authorities
Plants
Manufacturing capacity
• Investment for downstream and upstream facilities
• Project feasibility
Product
Business and Market Development
•Thailand (Self-sufficiency) and Export Network (Sustainability)
•Return on Investment, break even
From Constellation to Consolidation
Consolidation
I. Merieux Acambis
Sanofi
Aventis
Pasteur
Merck
P. Vaccins
Merck
Merck
Vaccines
IDB
Human
GSK
GSK Corixa
SSW
RIT
FIVE STARS
CONSOLIDATION
MARKET
PHASE
Sclavo Behring
Chiron
Novartis
Biotech C
Wyeth
Pfizer
Wyeth
Lederle
Crucell
SSI
Emerging S
Crucell
Rhein
B. GCVC SBL CSL
Berna Duphar
Baxter
Baxter Berna
Sevac NAVA
Immuno
Powderject
New Scenario in 2009
Consolidation
Emergence of New Players
New Wave of Consolidation
I. Merieux Acambis
Sanofi
Merck
P. Vaccins
Merck
IDB
Human
GSK Corixa
SSW
RIT
Sclavo Behring
Novartis
Powderject
Intercell
Biotech C
Wyeth
Crucell
J&J
Lederle
SSI
China
Emerging S
Crucell
Rhein
B. GCVC SBL CSL
Duphar
Baxter Berna
Sevac NAVA
Immuno
India
Current Vaccine Production/Filling Capacity in ASEAN
10
10
9
8
8
8
7
Number of Vaccines
7
6
Filling
5
Production
4
3
2
2
2
1
1
0
0
Thailand
Indonesia
Vietnam
Singapore
Vaccines
F
Rabies, DTwP, HB,
Mea, JE, Flu
HB, Flu
HB
-
P
BCG, JE
DTwP, OPV, Mea,
Hib, BCG
DTwP, OPV, BCG,
Mea, JE, Flu
Pneu (10-valent)
Bringing in International Vaccine Expertise
Experienced Vaccine Management Team
Vitoon
Vonghangool
Pham Hong Thai
Jean Petre
Nadir Harjee
CEO.
Scientific Dir.
Technical Dir.
President
20 years
Biocine (France)
Chiron (Italy)
28+7 years
SKB (Belgium)
Chiron(Italy)
PATH consultant
37 years
PM Connaught
(Canada)
WHO consultant
42 years
Pasteur Mérieux
(Thailand)
Chiron consultant
Dario Cresci
Site Director
15+12 years
AstraZeneca
Novartis (Italy)
8
Rochapon
Wacharotayankun
Athapume
Thamrongyuth
Head, Quality Ops
Validation
Manager
10 years
GPO-MBP
(Thailand)
11+29 years
Hoechst, GPOMBP (Thailand)
Veerachai
Tarnmaneewongse
Marketing Director
22 years
Sanofi Pasteur
(Thailand)
Indrajeet Poredi
Mukesh Chauhan
Research Manager
Development
Manager
15 years
Serum Institute
Panacea Biotec
Shantha, Biotechnics
(India)
11 years
Panacea Biotec
Shantha
Biotechnics (India)
Broad Product Pipeline
Acellular
pertussis
Human
papilloma
Hepatitis B
TdaP
Hib
meningitis
Dengue
2011
Y
DTaP-HB
DTaP-HB-Hib
Diphtheria
2006-2007
9
1
Tetanus
Viral
Cell culture
Protein
Bacterial Recombinant
conjugation Combination
protein
In-house and Licensed Technology Platforms
Protein
carrier
1
Japanese
Encephalitis
2012
Chikungunya
HIV?
HIV ?
2013
1
BioNet-Asia Employees by Education Level
Total 114
120
13
Number of employees
100
31
80
PhD
9
60
MSc
Pharmacist
BSc
40
38
20
9
14
0
2001-2007
2008
2009
2010
2011
2012
Voc
High
Building up Vaccine Capability in Thailand
Fast-track Process
In-house Training
People – Expertise/Skill
PhD
2001-2007
2012
Project – Technology
Plant – Facility
11
Vaccine Collaboration
National Agenda for Vaccine
Vaccine Plant
Pilot Plant from 2006 to 2011
12
Vaccine Plant
Three Dedicated Buildings for Production, QC, R&D
Production
R&D
Quality Control
13
P15 activities progress
Vaccine Plant
Medium to Large Scale Bulk Manufacturing Capacities
Bulk Antigen Manufacturing Capacity
(Total doses per year)
Acellular Pertussis
Hepatitis B
Haemophilus Influenzae
type b
Several million doses*
Diphtheria
* Depending on antigen produced and assuming
production of one antigen per year
15
Vaccine Plant - Site Master Plan
The Largest Vaccine Facility in Thailand (in 2015-2017)
16
Benefits of Building Vaccine Capacity to Thailand
Knowledge and innovation – Key driving factors for sustainable and economic growth in the 21st century
Vaccine self-sufficiency
- Improved quality of life
- National Security
Knowledge pool
Employment
- Sustaining knowledge creation
- Strengthening scientific community
- Attracting talents
- Increased R&D funds for translational
research (High R&D fund/GDP)
- Increased job opportunity;
professional and skilled
workers
- Income distribution
Competitiveness
- Increased research / business opportunity
- Attracting foreign or multinational
companies for business collaboration
Human resource development
Academics, Researcher, Developer,
Manufacturer, Regulator
Emergence of local vaccine-related
business/industries
17
Economic stimulus
package
- Rapid growth of GDP
Return of value
to research
“Long term
income” for
creation of a strong
stream of profits